Form 8-K - Current report:
SEC Accession No. 0001641172-25-009775
Filing Date
2025-05-13
Accepted
2025-05-12 19:29:22
Documents
15
Period of Report
2025-05-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 39925
2 EX-10.1 ex10-1.htm EX-10.1 56488
  Complete submission text file 0001641172-25-009775.txt   283713

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE imnn-20250512.xsd EX-101.SCH 3008
4 XBRL LABEL FILE imnn-20250512_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE imnn-20250512_pre.xml EX-101.PRE 22354
18 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3688
Mailing Address 997 LENOX DRIVE SUITE 100 LAWRENCEVILLE NJ 08648
Business Address 997 LENOX DRIVE SUITE 100 LAWRENCEVILLE NJ 08648 (609) 896-9100
Imunon, Inc. (Filer) CIK: 0000749647 (see all company filings)

EIN.: 521256615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-15911 | Film No.: 25936626
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)